Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients

PURPOSE To investigate the relationship between the dynamic parameters (Ki) and static image-derived parameters of 68Ga-DOTATOC-PET, to determine which static parameter best reflects underlying somatostatin-receptor-expression (SSR) levels on neuroendocrine tumours (NETs). PATIENTS, METHODS 20 patients with metastasized NETs underwent a dynamic and static 68Ga-DOTATOC-PET before PRRT and at 7 and 40 weeks after the first administration of 90Y-DOTATOC (in total 4 cycles were planned); 175 lesions were defined and analyzed on the dynamic as well as static scans. Quantitative analysis was performed using the software PMOD. One to five target lesions per patient were chosen and delineated manually on the baseline dynamic scan and further, on the corresponding static 68Ga-DOTATOC-PET and the dynamic and static 68Ga-DOTATOC-PET at the other time-points; SUVmax and SUVmean of the lesions was assessed on the other six scans. The input function was retrieved from the abdominal aorta on the images. Further on, Ki was calculated using the Patlak-Plot. At last, 5 reference regions for normalization of SUVtumour were delineated on the static scans resulting in 5 ratios (SUVratio). RESULTS SUVmax and SUVmean of the tumoural lesions on the dynamic 68Ga-DOTATOC-PET had a very strong correlation with the corresponding parameters in the static scan (R²: 0.94 and 0.95 respectively). SUVmax, SUVmean and Ki of the lesions showed a good linear correlation; the SUVratios correlated poorly with Ki. A significantly better correlation was noticed between Ki and SUVtumour(max and mean) (p < 0.0001). CONCLUSIONS As the dynamic parameter Ki correlates best with the absolute SUVtumour, SUVtumour best reflects underlying SSR-levels in NETs.

[1]  Liane Oehme,et al.  The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG , 2013, EJNMMI Research.

[2]  O. Nanni,et al.  Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  F. Minuto,et al.  Pre-surgical treatment with somatostatin analogues in patients with acromegaly: The case for , 2012, Journal of Endocrinological Investigation.

[4]  F. Mottaghy,et al.  Functional imaging of neuroendocrine tumors. , 2011, Methods in molecular biology.

[5]  P. Cumming,et al.  68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors , 2010, The Journal of Nuclear Medicine.

[6]  J. Yap,et al.  Comparison of standardized measurement of SUVmax versus a threshold-based SUVmean in cancer response assessment using FDG-PET , 2010 .

[7]  V. Cuccurullo,et al.  The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[8]  M. Pawlikowski,et al.  SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. , 2010, Folia histochemica et cytobiologica.

[9]  R. Bale,et al.  Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy , 2009, Journal of Nuclear Medicine.

[10]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[11]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[13]  Anders Sundin,et al.  Nuclear imaging of neuroendocrine tumours. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[14]  A. Balbarini,et al.  Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages , 2007, Journal of leukocyte biology.

[15]  Uwe Haberkorn,et al.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Ludwig G Strauss,et al.  Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  W. H. Knapp,et al.  68Ga-labelled DOTA-derivatised peptide ligands , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Christian Bruns,et al.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.

[20]  Uwe Haberkorn,et al.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[21]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[22]  U. Haberkorn,et al.  PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[24]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.